The Food and Drug Administration said Thursday that accumulating evidence suggests a Bayer AG drug used to prevent excessive bleeding during heart bypass surgery increases the risk of death when compared with other drugs.
The announcement came as a Canadian study comparing the safety and efficacy of the drug, Trasylol, with two others was halted. Preliminary results from that trial also suggested Trasylol increased the risk of death when compared with the other drugs. The trial was to include 3,000 patients.